Quarterly Sales (Approved)
November 3, 2020 (Est)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Quarterly Sales for Vascepa used to lower cholesterol (FDA-approved drug)
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Past Quarterly Revenue ( See Graph Below)
11-12-2018 Reduce-It MACE trial results
08-2020: Investor Update
MECHANISM OF ACTION/RATIONALE
Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.
FDA Drug Label (slide 5, section 12.1)
Updated by HC
#AMRN, #Vascepa, #Vascepa, #icosapent_ethyl
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post